Research & Development
Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA
19 January 2022 - - US-based Omeros Corp. (NASDAQ: OMER) has confirmed that earlier this month the company submitted to the US Food and Drug Administration its response to the Agency's Complete R...
US FDA Approves Pfizer's Cibinqo for Adults with Moderate-to-Severe Atopic Dermatitis
19 January 2022 - - The United States Food and Drug Administration approved Cibinqo (abrocitinib), an oral, once-daily, Janus kinase 1 inhibitor, for the treatment of adults living with refractory, mo...
US Merck, Ridgeback Ink Supply Agreement with UNICEF for Investigational Oral Antiviral COVID-19 Medicine Molnupiravir
19 January 2022 - - US-based pharmaceutical company Merck (NYSE: MRK) and US-based biotechnology company Ridgeback Biotherapeutics have signed a long-term supply agreement with the United Nations Chil...
Aditxt Submits Two Requests for Emergency Use Authorization to FDA for AditxtScore for COVID-19 Tests Which Measure the Quantity and Quality of Antibodies Against COVID-19 and its Variants Including Omicron
19 January 2022 - - US-based biotech innovation company Aditxt, Inc (NASDAQ: ADTX) has submitted two EUA applications for AditxtScore for COVID-19, the company said.

The company said this...
BioInvent granted FDA orphan designation for follicular lymphoma
19 January 2022 - Swedish immuno-oncology company BioInvent International AB (STO:BINV) announced on Wednesday that it has received Orphan Drug Designation (ODD) in the United States for its anti-FcyR...
ExThera Medical Corporation concludes patient enrollment in DOD funded study of Seraph 100 in critically ill COVID-19 Patients
19 January 2022 - Blood purification company ExThera Medical Corporation stated on Tuesday that critically-ill COVID patients treated with the Seraph 100 Microbind Affinity Blood Filter (Seraph 100) h...